

# PrEP : quel impact dans le monde ?

O. Epaulard  
Infectiologie  
CHU de Grenoble


# Différentes questions

- Quel impact sur l'épidémiologie du VIH ?
  - Dans les villes/territoires qui l'ont mis en place au début des années 2010 ?
  - Ou plus tard ...
  - Au niveau national ? Et international ?
- Quel impact sur l'épidémiologie des IST ?

## ORIGINAL ARTICLE

# On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

J.-M. Molina, C. Capitant, B. Spire, G. Pialoux, L. Cotte, I. Charreau, C. Tremblay,  
J.-M. Le Gall, E. Cua, A. Pasquet, F. Raffi, C. Pintado, C. Chidiac, J. Chas,  
P. Charbonneau, C. Delaugerre, M. Suzan-Monti, B. Loze, J. Fonsart, G. Peytavin,  
A. Cheret, J. Timsit, G. Girard, N. Lorente, M. Préau, J.F. Rooney, M.A. Wainberg,  
D. Thompson, W. Rozenbaum, V. Doré, L. Marchand, M.-C. Simon, N. Etien,  
J.-P. Aboulker, L. Meyer, and J.-F. Delfraissy, for the ANRS IPERGAY Study Group\*



#### No. at Risk

Placebo	201	141	74	55	42
TDF-FTC	199	141	82	58	43

---

# Ending the HIV–AIDS Pandemic — Follow the Science

Anthony S. Fauci, M.D., and Hilary D. Marston, M.D., M.P.H.

Related article, p. 2237

The  
science has spoken. There can  
now be no excuse for inaction.





[Home](#) / [News](#) / WHO launched new implementation guidance for simplified and differentiated service delivery of pre-exposure prophylaxis (PrEP)



Credits




## WHO launched new implementation guidance for simplified and differentiated service delivery of pre-exposure prophylaxis (PrEP)


# Global PrEP Network Highlight - March 2021

16 March 2021

Data compiled by the Global PrEP Network, shown in the [Global State of PrEP](#) shows that oral PrEP use has been increasing globally and over 600 000 people across 76 countries received PrEP at least once in 2019 – a 70% increase from 2018.



## Number of oral PrEP users in each WHO member state in 2020






# No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting

**Jonathan E. Volk,<sup>1</sup> Julia L. Marcus,<sup>2</sup> Tony Phengrasamy,<sup>1</sup>  
Derek Blechinger,<sup>1</sup> Dong Phuong Nguyen,<sup>1</sup> Stephen Follansbee,<sup>1</sup> and  
C. Bradley Hare<sup>1</sup>**

<sup>1</sup>Department of Adult and Family Medicine, Kaiser Permanente San Francisco Medical Center, and <sup>2</sup>Division of Research, Kaiser Permanente Northern California, Oakland, California



**Figure 1.** Human immunodeficiency virus preexposure prophylaxis (PrEP) referrals, intakes, and initiation by month at Kaiser Permanente San Francisco, July 2012–February 2015. The graph includes a total of 1045 referrals, 835 intakes, and 677 initiations, including 20 individuals who restarted PrEP after discontinuing during the study period.

# HIV EPIDEMIOLOGY

## Annual Report 2021


### San Francisco

Department of Public Health  
Population Health Division





**Figure 1.1 HIV disease stage 3 (AIDS) diagnoses, deaths, and prevalence, 1980-2021, San Francisco**




<sup>1</sup> Death reporting for 2021 is not complete.





People living with HIV  
New HIV diagnoses  
Deaths


# HIV Diagnoses, Deaths and Prevalence 2006–2021, San Francisco








**Figure 2.4 Number of cis men newly diagnosed with HIV by transmission category, 2012-2021, San Francisco**




1 Includes people with HIV by year of their initial HIV diagnosis.

**Figure 16.1 Proportion of MSM currently on PrEP<sup>1</sup> by race/ethnicity, San Francisco City Clinic patients, 2014-2021**



<sup>1</sup> On PrEP at visit: (1) Answer 'yes' to are you currently on PrEP or (2) Enrolled in PrEP as of visit.




# HIV Surveillance Annual Report, 2020

New York City Department of Health and Mental Hygiene



## History of the HIV Epidemic

Figure 1.1: History of the HIV epidemic, NYC 1981-2020




\*Data on 2020 deaths are incomplete.




## Estimated HIV Incidence

**Figure 10.1:** New HIV diagnoses and estimated incident HIV infections<sup>1</sup>, NYC 2016-2020<sup>2</sup>



**Figure 10.2:** Trends in estimated incident HIV infections<sup>1</sup> by sex at birth<sup>3</sup> and transmission category, NYC 2016-2020<sup>2</sup>






2020

# HIV/STI SURVEILLANCE REPORT

2020




**Figure 2.1:** People Living with HIV Infection (PLWH), People Diagnosed with HIV Infection, People Diagnosed with AIDS, Concurrent HIV/AIDS Diagnoses, and Deaths Among PLWH, Chicago, 1990-2019 (as of 9/28/2020)








**Figure 2.2:** Number of Reported Sexually Transmitted Infections, Chicago, 1997-2019



## Oral PrEP Uptake in the United States



# Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012–2016


Dawn K. Smith,<sup>1,✉</sup> Patrick S. Sullivan,<sup>2</sup> Betsy Cadwell,<sup>1</sup> Lance A. Waller,<sup>3</sup> Azfar Siddiqi,<sup>1</sup> Robertino Mera-Giler,<sup>4</sup> Xiaohong Hu,<sup>1</sup> Karen W. Hoover,<sup>1</sup> Norma S. Harris,<sup>1</sup> and Scott McCallister<sup>4</sup>

<sup>1</sup>Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, <sup>2</sup>Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, <sup>3</sup>Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, and <sup>4</sup>Gilead Sciences, Foster City, California, USA


---



## Progression d'utilisation de la PrEP




Évolution du nombre de diagnostics VIH



Progression d'utilisation de la PrEP

# WHILE 25% OF PEOPLE ELIGIBLE FOR PREP WERE PRESCRIBED IT IN 2020, COVERAGE IS NOT EQUAL

PREP COVERAGE IN THE U.S. BY RACE/ETHNICITY, 2020




For more information, visit  
[cdc.gov/nchhstp/newsroom](https://cdc.gov/nchhstp/newsroom)



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

## NEW HIV INFECTIONS FELL 8% FROM 2015 TO 2019, AFTER A PERIOD OF GENERAL STABILITY

ANNUAL HIV INFECTIONS IN THE U.S., 2015-2019




For more information, visit  
[cdc.gov/nchhstp/newsroom](https://www.cdc.gov/nchhstp/newsroom)



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention




# Chlamydia — Rates of Reported Cases by Year, United States, 1984–2020



\* Per 100,000




# Chlamydia — Rates of Reported Cases by Sex, United States, 2011–2020




\* Per 100,000

# Gonorrhea — Rates of Reported Cases by Year, United States, 1941–2020




\* Per 100,000

# Gonorrhea — Rates of Reported Cases by Sex, United States, 2011–2020



\* Per 100,000


# *Neisseria gonorrhoeae* — Percentage of Urethral Isolates Obtained from MSM Attending STD Clinics, Gonococcal Isolate Surveillance Project (GISP), 1989–2020



**ACRONYMS:** MSM = Gay, bisexual, and other men who have sex with men




# Syphilis — Rates of Reported Cases by Stage of Infection, United States, 2011–2020




\* Per 100,000

# Primary and Secondary Syphilis — Rates of Reported Cases by Region, United States, 2011–2020



\* Per 100,000


# Primary and Secondary Syphilis — Reported Cases by Sex and Sex of Sex Partners, United States, 2016–2020



**ACRONYMS:** MSM = Gay, bisexual, and other men who have sex with men; MSU = Men with unknown sex of sex partners; MSW = Men who have sex with women only

**NOTE:** Over the five year period, 0.2% of cases were missing sex and were not included.




# Primary and Secondary Syphilis — Reported Cases Among Men Who Have Sex with Men by HIV Status, United States, 2011–2020







## **ORIGINAL RESEARCH**

# **The success of HIV combination prevention: The Dean Street model**

**Nicolò Girometti<sup>1</sup> | Valerie Delpech<sup>2</sup>  | Sheena McCormack<sup>1,3</sup> | Jameel Khawam<sup>2</sup> | Sophie Nash<sup>2</sup>  | Dana Ogaz<sup>2</sup> | Hamish Mohammed<sup>2</sup> | Keerti Gedela<sup>1</sup> | Diarmuid Nugent<sup>1</sup> | Sheel Patel<sup>1</sup> | Tara Suchak<sup>1</sup> | Victoria Tittle<sup>1</sup> | Alan McOwan<sup>1</sup> | Gary Whitlock<sup>1</sup> **




**FIGURE 3** Post-exposure prophylaxis following sexual exposure (PEPSE) and pre-exposure prophylaxis (PrEP) users over time. The number of PEPSE prescriptions (dark grey line) dispensed each month between January 2012 and December 2017 and the number of unique PrEP users (light grey line) over the same period at 56 Dean Street





# **Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes**

**Nicolò Girometti<sup>a</sup>, Sheena McCormack<sup>a,b</sup>, Victoria Tittle<sup>a</sup>,  
Alan McOwan<sup>a</sup>, Gary Whitlock<sup>a</sup>, on behalf of the 56 Dean Street  
Collaborative Group**



[Home](#) > [Health and social care](#) > [Public health](#) > [Health protection](#) > [Health surveillance and reporting programmes](#)  
> [HIV: annual data tables](#)



[UK Health](#)  
[Security](#)  
[Agency](#)


Official Statistics

# HIV testing, PrEP, new HIV diagnoses, and care outcomes for people accessing HIV services: 2022 report

Updated 4 October 2022



**Figure 5. New HIV diagnoses, AIDS at diagnosis, and all-cause deaths in people with HIV: England, 2002 to 2021**





# Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany


Daniel Schmidt<sup>1</sup> · Christian Kollan<sup>1</sup> · Barbara Bartmeyer<sup>1</sup> · Viviane Bremer<sup>1</sup> · Tim Schikowski<sup>1</sup> · Martin Friebe<sup>1</sup> · Sven Schellberg<sup>2</sup> · Stefan Scholten<sup>3</sup> · Markus Bickel<sup>4</sup> · Nikola Hanhoff<sup>5</sup> · Robin Rüsenberg<sup>5</sup> · Knud Schewe<sup>5</sup> · The NEPOS study group

Received: 25 June 2022 / Accepted: 29 August 2022

© The Author(s) 2022


### Incidence of Chlamydia under PrEP

Incidence rate    Positivity rate    Number of STI tests




### Incidence of Gonorrhoe under PrEP

Incidence rate    Positivity rate    Number of STI tests



### Incidence of Syphilis under PrEP

Incidence rate    Positivity rate    Number of STI tests






# Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe

*Bruno Sepodes<sup>1,2\*</sup>, João Rocha<sup>1,2</sup>, Jorge Batista<sup>3</sup>, Maria-Eduardo Figueira<sup>2,4</sup>, František Dráfi<sup>5</sup> and Carla Torre<sup>1,2</sup>*




-  Nationally available (reimbursed)
-  Ongoing pilot research project
-  Generic PrEP available in healthcare settings (not fully reimbursed)
-  Not formally implemented



**FIGURE 3** | Status of PrEP implementation in Europe and Central Asia by October 2020 based on data reported by ECDC in the implementation, standards, and monitoring operational guidance; created using mapchart.net (8).

**Figure 1.13a: HIV diagnoses, by year of diagnosis and transmission mode, EU/EEA, 2011–2020**



Data from 22 EU/EEA countries included. HIV diagnoses reported by Iceland, Ireland, Lithuania, Malta and Poland are excluded due to incomplete reporting on transmission mode for some years of the period; diagnoses reported by Portugal, Italy and Spain are excluded due to incomplete reporting during a portion of the period.




## SURVEILLANCE REPORT

# Chlamydia infection

Annual Epidemiological Report for 2019

**Figure 3. Number of confirmed chlamydia cases by sex and year in EU/EEA countries reporting consistently, 2010–2019**






## SURVEILLANCE REPORT


# Syphilis

Annual Epidemiological Report for 2019

**Figure 4. Number of confirmed syphilis cases by gender and year in EU/EEA countries reporting consistently, 2010–2019**



**Figure 5.** Number of confirmed syphilis cases by gender, transmission category and year in EU/EEA countries reporting consistently, 2010–2019



[Health Topics](#) ▾[Countries](#) ▾[Newsroom](#) ▾[Emergencies](#) ▾

[Home](#) / [News](#) / **WHO recommends long-acting cabotegravir for HIV prevention**

# WHO recommends long-acting cabotegravir for HIV prevention

**New WHO guidelines advise countries to deliver long-acting cabotegravir as part of comprehensive approach to HIV prevention**

28 July 2022 | News release | Reading time: 3 min (830 words)